

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 1, 2021**

NextCure, Inc.

(Exact name of registrant as specified in charter)

Delaware (State or other jurisdiction of incorporation)	001-38905 (Commission File Number)	47-5231247 (IRS Employer Identification No.)
9000 Virginia Manor Road, Suite 200 Beltsville, Maryland (Address of principal executive offices)		20705 (Zip Code)

(240) 399-4900

Registrant's telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	NXTC	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On October 1, 2021, the Board of Directors (the “**Board**”) of NextCure, Inc. (the “**Company**”), following the recommendation of the nominating and corporate governance committee of the Board, elected Anne Borgman, M.D., and Ellen Feigal, M.D., to the Board. Dr. Borgman will serve as a Class I member of the Board with a term expiring at the Company’s 2023 annual meeting of stockholders, and Dr. Feigal will serve as Class II member of the Board with a term expiring at the Company’s 2024 annual meeting of stockholders and until their successors are duly elected and qualified or their earlier resignation, retirement, or removal. Dr. Borgman has been appointed as a member of the Nominating and Governance Committee of the Board. Dr. Feigal has been appointed as a member of the Compensation Committee of the Board. Both Drs. Borgman and Feigal have been determined to be independent directors.

Dr. Borgman has served as Vice President and Global Therapeutic Area Lead, Hematology-Oncology of Jazz Pharmaceuticals plc, a global biopharmaceutical company, since 2019. Prior to that, she served as Vice President, Clinical Research & Development at Exelixis Biopharmaceuticals, Inc. from 2012 to 2019. Dr. Borgman completed her clinical and research fellowship at the University of California, Los Angeles, Section of Pediatric Hematology Oncology and Bone Marrow Transplant, and prior to that completed her pediatric residency at Baylor College of Medicine/Texas Children’s Hospital. Dr. Borgman received her Bachelor of Science in Biochemistry from the University of Illinois and received her M.D. from the Loyola University of Chicago Stritch School of Medicine. Dr. Borgman is licensed to practice medicine in the states of California and Illinois. She currently holds an adjunct faculty member position at Stanford University School of Medicine, Department of Pediatrics, Division of Hematology, Oncology, Stem Cell, Transplantation, and Cancer Biology and is a clinical associate at the University of Chicago, Department of Pediatric Oncology and Stem Cell Research.

Dr. Feigal has served as a Partner and Head of the Biologics Practice at NDA Partners LLC since 2014. NDA Partners is part of ProPharma Group, a life sciences management consulting and contract development organization. She currently serves as a board member for Xencor, Inc. Dr. Feigal was formerly Senior Vice President of Research and Development at the California Institute for Regenerative Medicine; Executive Medical Director, Global Development, at Amgen; and Chief Medical Officer at Insys Therapeutics. She was a Founding Director of the American Course on Drug Development and Regulatory Sciences at the University of California, San Francisco (UCSF). Prior to UCSF, Dr. Feigal was Director of Medical Devices and Imaging at the Critical Path Institute and Vice President of Clinical Sciences at the Translational Genomics Research Institute. Dr. Feigal received her M.D. from the University of California, Davis and completed an internal medicine residency at Stanford University and a hematology/oncology fellowship at University of California, San Francisco, and currently serves as an adjunct professor at Arizona State University Sandra Day O’Connor College of Law.

Drs. Borgman and Feigal will be compensated for their service on the Board in accordance with the Company’s Non-Employee Director Compensation Program as described in the Company’s definitive proxy statement filed on April 29, 2021. Additionally, the Company entered into a customary indemnification agreement with Drs. Borgman and Feigal in connection with their appointments to the Board.

Item 7.01 **Regulation FD Disclosure.**

On October 4, 2021, the Company issued a press release announcing Dr. Borgman and Dr. Feigal’s appointments to the Board. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1

Item 9.01. **Financial Statements and Exhibits.**

Exhibit No.	Description
--------------------	--------------------

99.1	Press release of NextCure, Inc. dated October 4, 2021.
104	Coverage Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 4, 2021

NEXTCURE, INC.

/s/ Steven P. Cobourn

Steven P. Cobourn
Chief Financial Officer



NextCure Announces New Appointments to its Board of Directors

BELTSVILLE, Md., October 4, 2021 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of Ellen G. Feigal, M.D., and Anne Borgman, M.D., to its Board of Directors.

“I am thrilled to welcome two new members to NextCure’s Board of Directors,” said Michael Richman, NextCure’s president and chief executive officer. “Both Dr. Feigal and Dr. Borgman bring extensive experience in clinical and biopharmaceutical settings. Their insights will be valuable as NextCure continues to advance multiple clinical programs and investigate and develop new immunomedicines for cancer patients. These appointments follow the resignation of Stella Xu, Ph.D. from the board as previously announced. In addition, we would like to thank Stella Xu for her commitment and support in building NextCure.”

Dr. Feigal is currently a Partner and Head of the Biologics Practice at NDA Partners LLC, a life sciences consulting and contract development organization, where she leads efforts in designing and executing product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology. Dr. Feigal is also adjunct faculty at the Sandra Day O’Connor College of Law, Arizona State University, where she teaches FDA drug law and medical research ethics and law. Her career includes over thirty years in clinical drug development, with roles spanning industry and academic medicine, including at the National Cancer Institute, where she served as Acting Director, Division of Cancer Treatment/Diagnosis during her tenure; Senior Vice President of Research and Development at the California Institute of Regenerative Medicine, and Executive Medical Director, global development at Amgen. She currently serves as a board member for Xencor. She earned her M.D. from the University of California, Davis, completed an internal medicine residency at Stanford University and a hematology/oncology fellowship at the University of California, San Francisco.

Dr. Borgman is currently Vice President and Global Therapeutic Area Lead, Hematology-Oncology, at Jazz Pharmaceuticals, where she is responsible for global development of the company’s oncology and hematology drugs, including four marketed products. Previously, Dr. Borgman was Vice President, Clinical Research & Development, at Exelixis, where she was a Clinical Lead in the global development for cabozantinib in oncology indications including renal cell, hepatocellular and thyroid carcinoma. Earlier she was Chief Medical Officer and Vice President of Hana Biosciences (Talon Therapeutics), where she oversaw all aspects of the company’s drug development operations. In addition, Dr. Borgman has worked as Associate Chief Medical Officer at KaloBios Pharmaceuticals, and she was formerly a Global Development Head at Abbott Pharmaceuticals (now AbbVie) where she was responsible for the early drug development of the PARP inhibitor, antimetabolic, and Bcl-2/Bcl-XL platforms. Dr. Borgman continues clinical involvement, as a Consulting Associate Professor at Stanford University School of Medicine’s Stem Cell Transplant & Cell Biology program, and as a Clinical Associate at University of Chicago’s Department of Pediatric Oncology and Stem Cell Research. Dr. Borgman completed her fellowship in pediatric hematology - oncology and stem cell transplant at UCLA David Geffen School of Medicine, trained in pediatrics at Texas Children’s Hospital, Baylor College of Medicine, and earned her M.D. from Loyola University of Chicago’s Stritch School of Medicine.

About NextCure, Inc.

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. <http://www.nextcure.com>

Cautionary Statement Regarding Forward-Looking Statements

Statements made in this press release that are not historical facts are forward-looking statements. Words such as “expects,” “believes,” “intends,” “hope,” “forward” and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure’s plans, objectives and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including NextCure’s most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

Investor Inquiries

Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
